Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 5/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 3/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25599468 | 0.86 | GABRG2 (0.37) | SCN9AGABRG2GABRB3GABRA5BRD4 | |
| SCHEMBL25599512 | 0.81 | HTR2A (0.35) | SCN9ABRD4 | |
| SCHEMBL30591239 | 0.77 | SCN9A (0.35) | SCN9AGABRG2GABRB3GABRA5BRD4 | |
| SCHEMBL25599471 | 0.77 | SCN9A (0.35) | SCN9AGABRG2GABRB3GABRA5BRD4 | |
| SCHEMBL25599466 | 0.76 | HTR2A (0.41) | PIK3CA | |
| SCHEMBL30591217 | 0.76 | HTR2A (0.41) | PIK3CA | |
| SCHEMBL30591166 | 0.76 | ALOX5AP (0.37) | SCN9AGABRG2GABRB3GABRA5PIK3CA | |
| SCHEMBL25599510 | 0.70 | SCN9A (0.40) | SCN9A | |
| SCHEMBL19693521 | 0.69 | MEN1 (0.40) | — | |
| SCHEMBL29519464 | 0.69 | MEN1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317748-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | BIONOVA PHARMACEUTICALS LTD. (KY) | 2024-09-26 | — | — | US | disclosed |
| WO-2023098876-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | BIONOVA PHARMACEUTICALS (SHANGHAI) LIMITED (CN) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317748-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | SDHA, PDHA1, GLS | SCN9A 1269/4885GABRG2 211/4885GABRB3 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.